577 results
Search Results
2. Regulation of Drug Transport Proteins—From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium.
- Author
-
Brouwer, Kim L.R., Evers, Raymond, Hayden, Elizabeth, Hu, Shuiying, Li, Cindy Yanfei, Meyer zu Schwabedissen, Henriette E., Neuhoff, Sibylle, Oswald, Stefan, Piquette‐Miller, Micheline, Saran, Chitra, Sjöstedt, Noora, Sprowl, Jason A., Stahl, Simone H., and Yue, Wei
- Subjects
CARRIER proteins ,PROTEIN transport ,MEMBRANE transport proteins ,DRUG laws ,CONSORTIA ,LUNGS ,NUCLEAR receptors (Biochemistry) - Abstract
Membrane transport proteins are involved in the absorption, disposition, efficacy, and/or toxicity of many drugs. Numerous mechanisms (e.g., nuclear receptors, epigenetic gene regulation, microRNAs, alternative splicing, post‐translational modifications, and trafficking) regulate transport protein levels, localization, and function. Various factors associated with disease, medications, and dietary constituents, for example, may alter the regulation and activity of transport proteins in the intestine, liver, kidneys, brain, lungs, placenta, and other important sites, such as tumor tissue. This white paper reviews key mechanisms and regulatory factors that alter the function of clinically relevant transport proteins involved in drug disposition. Current considerations with in vitro and in vivo models that are used to investigate transporter regulation are discussed, including strengths, limitations, and the inherent challenges in predicting the impact of changes due to regulation of one transporter on compensatory pathways and overall drug disposition. In addition, translation and scaling of in vitro observations to in vivo outcomes are considered. The importance of incorporating altered transporter regulation in modeling and simulation approaches to predict the clinical impact on drug disposition is also discussed. Regulation of transporters is highly complex and, therefore, identification of knowledge gaps will aid in directing future research to expand our understanding of clinically relevant molecular mechanisms of transporter regulation. This information is critical to the development of tools and approaches to improve therapeutic outcomes by predicting more accurately the impact of regulation‐mediated changes in transporter function on drug disposition and response. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population.
- Author
-
van Riet‐Nales, Diana A., van den Bemt, Bart, van Bodegom, David, Cerreta, Francesca, Dooley, Brian, Eggenschwyler, Doris, Hirschlérova, Blanka, Jansen, Paul A. F., Karapinar‐Çarkit, Fatma, Moran, Abigail, Span, Jan, Stegemann, Sven, and Sundberg, Katarina
- Subjects
OLDER patients ,OLDER people ,MEDICAL personnel ,POPULATION aging ,DRUG laws ,DRUGS - Abstract
Older people are often affected by impaired organ and bodily functions resulting in multimorbidity and polypharmacy, turning them into the main user group of many medicines. Very often, medicines have not specifically been developed for older people, causing practical medication problems for them like limited availability of easy to swallow formulations, easy to open packaging and dosing instructions for enteral administration. In 2020, the European Medicines Agency (EMA) published a reflection paper 'Pharmaceutical development of medicines for use in the older population', which discusses how the emerging needs of an ageing European population can be addressed by medicines regulation. The paper intends to help industry to better consider the needs of older people during pharmaceutical/clinical medicines development by summarising data on the most relevant topics, providing early suggestions on how to move forward and prompting expert discussions and studies into knowledge gaps. Topics include patient acceptability, (dis)advantages of an administration route, formulation, dosage form, packaging, dosing device and user instruction. While the paper is directed at older people and the pharmaceutical industry, the reflections are also relevant to younger patients with similar disease‐related needs and of value to other stakeholders parties, e.g., healthcare professionals, academics, patients and caregivers, as the paper makes clear what can be expected from industry and where collaborative work is needed. This commentary provides an overview of the different steps in the development of the reflection paper, discusses points considered most controversial and/or subject to (multidisciplinary) expert discussions and indicates their value for real world clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. LA REGULACIÓN LEGAL DE LA MARIHUANA EN URUGUAY: UNA APROXIMACIÓN DESDE LA PERSPECTIVA DE LAS POLÍTICAS MORALES Y LAS IDEAS (1974-2013).
- Author
-
Labiano, Virginia
- Subjects
MARIJUANA legalization ,PHARMACEUTICAL policy ,DRUG laws ,MARIJUANA ,LEADERSHIP ,LEGALIZATION - Abstract
Copyright of Colección is the property of Pontificia Universidad Catolica Argentina and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
5. Impact of drug price regulation on patient access to medicines: A systematic review.
- Author
-
Ashiwaju, Bankole, Orikpete, Ochuko, Alade, Elesho, Raji, Ahmed, Adesanya, Abel, and Nwankwo, Tochukwu
- Subjects
PRICE regulation ,DRUG laws ,DRUG prices ,GENERIC drugs ,HEALTH care reform ,REFERENCE pricing - Abstract
This systematic review explored the multifaceted impact of drug price regulation on patient access to essential medicines. Recognizing the complexity of this relationship, the paper investigates the influence of various types of drug price regulation mechanisms, the disparities across different geographical regions and health-care systems, and the differential effects between branded and generic drugs. Our findings illustrate that the effects of drug price regulation are not universally uniform or predictable, but rather, they are highly context dependent. Direct price control measures can, on the one hand, improve accessibility through affordability; yet on the other hand, potentially disrupt drug supply. Indirect price control methods, such as reference pricing and value-based pricing, while designed to spur competition, can be hampered by administrative complexities and potentially stifle pharmaceutical innovation. Despite the pervasive use of drug price regulation, access to essential medicines remains disparate and inequitable, indicating a need for a comprehensive approach that includes health system reforms, improved health literacy, and greater collaboration between stakeholders. Future research should further investigate the enduring disparities in patient access to medicines, the long-term effects of various pricing mechanisms, and their interplay with the evolving pharmaceutical industry and health-care landscapes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Do Normative Issues Outperform Deterrence for Compliance With Drug Laws?
- Author
-
Quintas, Jorge
- Subjects
DRUG abuse ,DRUG laws ,COLLEGE students - Abstract
This article tests the impact of deterrence and normative variables in the estimation of drug use among both detected drug users and university students. Consistent with perceptual deterrence research, we expect: (a) a stronger effect of normative variables on estimation of drug use compared to deterrence variables and (b) that any deterrent effect would be restricted to detected drug users. In Portugal, we conducted a cross-sectional survey with detected drug users (N = 147) and with a sample of university students (N = 247). The main results show that normative variables outperform deterrent variables as predictors of intention to use drugs. Descriptive norms have a greater influence on the estimation of drug use in both groups, and proximal social norms have robust effects among university students. Core elements of the deterrence model are not related to the intention to use drugs. Personal certainty of being caught has even an unexpected positive correlation with this intention. A small deterrent effect is limited to the general certainty variable and only among more law-abiding people. The overall findings are consistent with a normative perspective on law compliance and highlight the importance of including all different normative and deterrent variables in models estimating drug use. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Legislating for Good Governance in the Pharmaceutical Sector through UN Convention Against Corruption (UNCAC) Compliance.
- Author
-
Wong, Anna, Perehudoff, Katrina, and Kohler, Jillian Clare
- Subjects
DRUG laws ,FRAUD prevention ,CORRUPTION prevention ,MEDICAL protocols ,HEALTH services accessibility ,ORGANIZATIONAL behavior ,RESEARCH funding ,CLINICAL governance ,PRIVACY ,RESPONSIBILITY ,DECISION making ,FRAUD ,MEDICAL ethics ,MANAGEMENT ,LAW ,LEGISLATION - Abstract
Pharmaceutical sector corruption undermines patient access to medicines by diverting public funds for private gain and exacerbating health inequities. This paper presents an analysis of UN Convention Against Corruption (UNCAC) compliance in seven countries and examines how full UNCAC adoption may reduce corruption risks within four key pharmaceutical decision-making points: product approval, formulary selection, procurement, and dispensing. Countries were selected based on their participation in the Medicines Transparency Alliance and the WHO Good Governance for Medicines Programme. Each country’s domestic anti-corruption laws and policies were catalogued and analysed to evaluate their implementation of select UNCAC Articles relevant to the pharmaceutical sector. Countries displayed high compliance with UNCAC provisions on procurement and the recognition of most public sector corruption offences. However, several countries do not penalise private sector bribery or provide statutory protection to whistleblowers or witnesses in corruption proceedings, suggesting that private sector pharmaceutical dispensing may be a decision-making point particularly vulnerable to corruption. Fully implementing the UNCAC is a meaningful first step that countries can take reduce pharmaceutical sector corruption. However, without broader commitment to cultures of transparency and institutional integrity, corruption legislation alone is likely insufficient to ensure long-term, sustainable pharmaceutical sector good governance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. 我国罕见病患者药品保障政策现状及改进思考.
- Author
-
于华燕 and 周良荣#
- Subjects
DRUG accessibility ,RARE diseases ,DRUG laws ,DEVELOPED countries ,DRUG development - Abstract
Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
9. Promoting the personal importation of therapeutic goods: recent legislative amendments to advertising regulations may impact consumer access and understanding.
- Author
-
Rudge, Christopher and Ghinea, Narcyz
- Subjects
TRANSPORTATION laws ,DRUGS & economics ,ADVERTISING laws ,DRUG approval ,HEALTH policy ,HEALTH services accessibility ,CLIENT relations ,CRITICISM ,INTERNET ,INVESTIGATIONAL drugs ,MEDICAL care costs ,DRUG laws ,HEALTH care reform ,COMMUNICATION ,CONSUMERS - Abstract
Objective: The personal importation scheme is a legislative mechanism that allows health consumers to import unapproved medicines under certain conditions. This article analyses the legal and policy basis for the scheme and considers how reforms to advertising laws for therapeutic goods may restrict communications about it. The article represents the first published analysis of the personal importation scheme's interaction with the communications of health professionals and buyer's clubs. It considers how these communications may be affected by legal amendments, particularly where unapproved medicines may be accessed through the scheme. Methods: An examination of Australian therapeutic goods law concerning the personal importation scheme was conducted, including both the historical law and recent regulatory reforms. Illustrative tables were prepared to identify scheme-related advertising that may contravene therapeutic goods law. Risk estimates were allocated to several new legal rules to indicate whether health professionals or buyer's clubs would contravene these laws when promoting the scheme to health consumers for unapproved medicines. Results: Representations made directly to the public by health practitioners or on buyer's clubs websites about accessing unapproved therapeutic goods through the personal importation scheme are likely to contravene one or more advertising laws. Conclusions: The Therapeutic Goods Administration has very strong powers to initiate compliance or enforcement action for advertising breaches in Australia for many promotional practices. Arguably, in the age of the internet and in the context of emerging expensive medicines, these powers should not be used to restrict health practitioners or buyer's clubs from sharing information about the lawful personal importation scheme to health consumers in need. Nevertheless, the study finds that health practitioners who promote or refer to the availability of unapproved medicines through the personal importation scheme outside of a consultation are likely to contravene the law and may be subject to disciplinary or enforcement action. What is known about the topic?. The personal importation scheme has not been studied extensively. This paper investigates whether recent updates to the advertising laws will affect the operation of the personal importation scheme and health practitioners' ability to refer to it in public. What does this paper add? This paper represents the first ever analysis of the way in which the personal importation scheme interacts with health practitioners' statements, buyer's clubs, and the internet. What are the implications for practitioners ? The study finds that health practitioners who promote the availability of unapproved medicines through the personal importation scheme outside professional consultations are likely to be liable to enforcement action from the Therapeutic Goods Administration. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. THE GREAT OVERDOSE GRIEF DIVIDE.
- Author
-
Siegel, Zachary
- Subjects
FENTANYL ,PARENT attitudes ,LEGAL status of drug dealers ,DRUG laws ,LAW enforcement - Abstract
The article focuses on the debate among parents regarding the fentanyl crisis and how to respond to it. Topics include parents advocating for stricter laws to hold drug dealers accountable, while others argue that such measures won't address the root causes and may have unintended consequences and need for aggressive drug enforcement.
- Published
- 2023
11. No smoking gun: tobacco taxation and smuggling in Sierra Leone.
- Author
-
Gallien, Max and Occhiali, Giovanni
- Subjects
DRUG laws ,CRIME prevention ,TAXATION ,EVALUATION of medical care ,MIDDLE-income countries ,GOVERNMENT policy ,LOW-income countries ,RESEARCH funding ,TOBACCO products ,TOBACCO - Published
- 2023
- Full Text
- View/download PDF
12. On the Judicialization of Health and Access to Medicines in Latin America.
- Author
-
Rama, Martín, Vargas, Verónica, Iunes, Roberto, and Guerra Junior, Augusto Afonso
- Subjects
HEALTH services accessibility laws ,DRUG laws ,OCCUPATIONAL roles ,MEDICAL laws ,HUMAN rights ,UNIVERSAL healthcare ,MEDICAL care costs ,QUALITY of life ,PROFESSIONAL autonomy ,LEGAL procedure ,PHYSICIANS ,DECISION making in clinical medicine - Abstract
In a context of rapid technological innovation and expensive new products, the paper calls for the generation of real-world data to inform decision-making and an international discussion on the affordability of new medicines, particularly for low- and middle-income countries. Without these, the challenges of health judicialization will continue to grow. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. An empirical analysis of overall survival in drug approvals by the US FDA (2006–2023).
- Author
-
Elbaz, Josh, Haslam, Alyson, and Prasad, Vinay
- Subjects
DRUG approval ,OVERALL survival ,DRUG laws ,ANTINEOPLASTIC agents ,BIOMARKERS - Abstract
Background: The US Food and Drug Administration (FDA) has expanded the use of surrogate markers in drugs approved for oncology/hematology indications. This has likely resulted in a greater number of approvals and possibly drugs coming to market faster, but it is unknown whether these drugs also improve overall survival (OS) for patients taking them. Methods: We sought to estimate the percentage of oncology drugs that have shown to improve OS in a cross‐sectional analysis of US FDA oncology drug approvals (2006–2023). We searched for OS data in registration trials and the peer‐reviewed literature. Results: We found 392 oncology drug approvals. Eighty‐seven (22%) drug approvals were based on OS, 147 drug approvals were later tested for OS benefit (38% of all approvals and 48% of drugs approved on a surrogate), and 130 (33%) have yet to be tested for OS benefit. Of the 147 drug approvals later tested for OS, 109 (28% of all approvals and 74% of drugs later tested for OS) have yet to show OS benefit, whereas 38 (10% of all approvals and 26% of drugs later tested for OS benefit) were later shown to have OS benefit. In total, 125 out of 392 (32%) drugs approved for any indication have been shown to improve OS benefit at some point, and 267 (68%) have yet to show approval. Conclusion: About 32% of all oncology drug approvals have evidence for an improvement in OS. Higher standards are needed in drug regulation to ensure that approved drugs are delivering better patient outcomes, specifically in regards to survival. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. The need to monitor emerging issues in etomidate usage: the misuse or abuse potential.
- Author
-
Uhm, Jiyeong, Hong, Songhee, and Han, Eunyoung
- Subjects
ETOMIDATE ,CONTROLLED drugs ,DRUG laws ,NARCOTICS ,MEDICATION safety - Abstract
Since 2011, the misuse or abuse of etomidate has gradually increased when propofol was designated a controlled drug under the Narcotics Control Act in Korea. Accordingly, the Ministry of Food and Drug Safety announced that etomidate would be under the 'Regulation on the designation of drugs that may cause concerns of misuse or abuse' rule in June 2020, which is less stringent than the Narcotics Control Act. Therefore, this review investigates potential misuse or abuse cases of etomidate to consider strengthening its management. A literature search was conducted to compare etomidate with other sedatives in their efficacy and side effects, as well as identify the adverse health outcomes, abuse cases, and analytical methods of etomidate. Etomidate has an equal or higher sedative efficacy and lower risk of adverse cardiopulmonary events than propofol. However, major adverse effects of etomidate include adrenocortical suppression and unproven associated deaths, as well as myoclonus requiring pre-treatment. Although the issue of abuse and misuse of etomidate is emerging in recent years, there are few academic reports on these issues and analytical methods in the forensic field. In order to effectively manage the misuse or abuse of etomidate, it is necessary to continuously monitor related cases with great interest and to be more intensively studied on its abuse potential. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. RETHINKING INNOVATION AT FDA.
- Author
-
SACHS, RACHEL E., PRICE II, W. NICHOLSON, and ZETTLER, PATRICIA J.
- Subjects
DRUG laws ,HEALTH policy ,MEDICAL laws ,MEDICARE laws - Abstract
In several controversial drug approval decisions in recent years, the Food & Drug Administration ("FDA") has publicly justified its decision partly on the ground that approving the drugs in question would support innovation in those fields going forward. To some observers, these arguments were surprising, as the Agency's determination whether a drug is "safe" and "effective" does not seem to depend on whether its approval also supports innovation. But FDA'suse of these innovation arguments in drug approval decisions is just one example of the ways in which the Agency has come to make many innovation-related judgments as part of its regulation of drugs. In this Article, we investigate the broad set of innovation-related judgments that FDA has been making and argue that there are serious concerns with the major innovation role FDA has been playing, at least as the Agency is currently constituted. We conclude that FDA should not separately weigh innovation in decisions about a product's safety and effectiveness. In other areas, health policymakers could reasonably decide that FDA should have either a larger or a smaller role than it currently does in shaping the development of novel drugs. But policymakers should do so while thoughtfully considering both the opportunities and challenges of FDA actively considering innovation incentives in its decisions; those challenges have been rarely considered in the literature and policy discourse. Further, we argue that whether policymakers aim to bolster or limit the ways that FDA considers innovation in its regulatory decisions, changes are needed to the Agency's structure to support its ability to make reasoned judgments based on relevant expertise. [ABSTRACT FROM AUTHOR]
- Published
- 2024
16. Medicalising the menace? The symbiotic convergence of medicine and law enforcement in the medicalisation of marijuana in Minnesota.
- Subjects
PROFESSIONAL ethics ,CLINICAL governance ,HEALTH services administration ,REGULATORY approval ,DRUG laws ,SOCIAL boundaries ,MEDICAL marijuana ,DISCOURSE analysis ,THERAPEUTICS - Abstract
The medicalisation of marijuana has occurred rapidly, albeit nonuniformly, across the US and around the world over the past 3 decades. This paper centres on the medicalisation of marijuana in Minnesota—which has one of the most restrictive programs in the country—as a case for evaluating the negotiation of institutional boundaries with the shift from criminalisation to medicalisation after nearly a century of criminal prohibition. Drawing upon Foucauldian discourse analyses of the medical and law enforcement associations' position statements and legislative hearings that shaped medical marijuana policy in Minnesota, this paper demonstrates a symbiotic convergence between medicine and law enforcement through the deployment of shared discursive strategies in their opposition to medical marijuana that reinforce marijuana's criminalised status by solidifying the boundaries between proper medicine and dangerous drugs. Criminal justice and medical institutions draw upon one another's definitions, logics, and practices in a mutually constitutive manner, while still maintaining distinct user subjects and institutional interventions for each based on the user's access to state‐approved forms of marijuana. The consequences for the governing of marijuana in Minnesota are explored, as well as the broader implications for the sociological study of medicalisation and criminalisation with respect to the governance of drugs and health. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Lessons from Canada's notice of compliance with conditions policy for the life-cycle regulation of drugs.
- Author
-
McPhail, Melanie, Zhang, Howard, Bhimani, Zohra, and Bubela, Tania
- Subjects
DRUG laws ,CLINICAL trials ,APPROPRIATE technology ,MEDICAL technology ,REGULATORY reform - Abstract
Innovative health technologies are not well regulated under current pathways, leading regulators to adopt contextual, life-cycle regulatory models, which authorize drugs based on earlier clinical evidence subject to the conduct of post-market trials that confirm clinical benefit and safety. In this paper, we evaluate all drugs authorized in Canada under the Notice of Compliance with conditions (NOC/c) policy from 1998 to 2021 to analyze its function, identify challenges and areas for improvement, and make recommendations to inform Health Canada's regulatory reforms. We analyzed a sample of 148 drugs authorized between 1998 and 2021, including characteristics about the pre- and post-market clinical trials, finding that most NOC/c authorizations are based on one, single-arm clinical trial using a surrogate endpoint. Post-market trials are more likely to be randomized, Phase III trials but mostly use surrogate endpoints. Based on our findings, we recommend increasing decision-making transparency throughout the regulatory process, developing comprehensive eligibility criteria for selecting appropriate health technologies, modernizing pre-market evidence requirements, adopting a more active role in designing post-market trials, and utilizing automatic expiry, stronger penalties, and ongoing disclosure of the status of post-market trials to promote compliance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Mystifying medicines and maximising profit: Antibiotic distribution in community pharmacies in Thailand.
- Author
-
Poompruek, Panoopat, Perris, Anna, Whanpuch, Phakha, Chandler, Clare I. R., and Sringernyuang, Luechai
- Subjects
DRUGS & economics ,DRUG laws ,ANTIMICROBIAL stewardship ,DRUG delivery systems ,FOCUS groups ,HEALTH services accessibility ,DRUGSTORES ,RESEARCH methodology ,ANTI-infective agents ,COMMUNITY health services ,DRUG resistance ,INTERVIEWING ,MEDICAL care costs ,MEDICAL care ,INAPPROPRIATE prescribing (Medicine) ,ETHNOLOGY research ,SURVEYS ,QUALITATIVE research ,INFORMED consent (Medical law) ,RESEARCH funding ,PROFIT ,DRUG utilization ,PARTICIPANT observation ,JUDGMENT sampling - Abstract
Thailand's antimicrobial stewardship strategy has focussed on promoting 'rational drug use' in the public sector, to reduce the threat of drug resistance and control healthcare expenditure. The strategy's next ambition is to attend to the private sector, where antibiotics are widely available over the counter without prescription. Using ethnographic and survey data, this paper follows antibiotics through community pharmacies, to explore drug distribution and access, and identify potential challenges for stewardship. We extend the analytical frame beyond 'irrational' dispenser-customer transactions, to explore the logics of practice of a multiplicity of actors in the context of a highly competitive pharmaceutical market. Highlighting the role of the pharmaceutical industry in mystifying medicines, we show how antibiotics are collapsed into a category of 'strong medicines' and requested by customers using 'prescriptions by proxy'. We further examine how Thailand's drug regulation and classificatory systems, historically orientated around access to medicines, enable the proliferation of antibiotics in the context of contemporary efforts to control distribution. Recognising the negotiations involved in dispensing antibiotics in a pluralistic health system, we attempt to reconfigure allocations of responsibility, advocating for stewardship approaches that take into account local ecologies of care, as well as implications for access, equity, and accountability. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Evolution and simulation of drug safety regulations: construction of a game model for capture event.
- Author
-
Wan, Anxia, Huang, Qianqian, Elahi, Ehsan, and Peng, Benhong
- Subjects
SAFETY regulations ,DRUG laws ,MEDICATION safety ,PROSPECT theory ,NASH equilibrium - Abstract
Purpose: The study focuses on drug safety regulation capture, reveals the inner mechanism and evolutionary characteristics of drug safety regulation capture and provides suggestions for effective regulation by pharmacovigilance. Design/methodology/approach: The article introduces prospect theory into the game strategy analysis of drug safety events, constructs a benefit perception matrix based on psychological perception and analyzes the risk selection strategies and constraints on stable outcomes for both drug companies and drug regulatory authorities. Moreover, simulation was used to analyze the choice of results of different parameters on the game strategy. Findings: The results found that the system does not have a stable equilibrium strategy under the role of cognitive psychology. The risk transfer coefficient, penalty cost, risk loss, regulatory benefit, regulatory success probability and risk discount coefficient directly acted in the direction of system evolution toward the system stable strategy. There is a critical effect on the behavioral strategies of drug manufacturers and drug supervisors, which exceeds a certain intensity before the behavioral strategies in repeated games tend to stabilize. Originality/value: In this article, the authors constructed the perceived benefit matrix through the prospect value function to analyze the behavioral evolution game strategies of drug companies and FDA in the regulatory process, and to evaluate the evolution law of each factor. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Drug Shortages: Policy Update.
- Author
-
Tapay, Nicole
- Subjects
DRUG laws ,GENERIC drug laws ,POLICY sciences ,HEALTH insurance reimbursement ,PROSPECTIVE payment systems ,LEGISLATION ,NEGOTIATION ,INVENTORY shortages ,MEDICAL supplies ,SUPPLY chains ,MANUFACTURING industries ,DRUGS ,MEDICAID ,PROFESSIONAL standards ,POLITICAL participation ,COMMITTEES - Published
- 2024
- Full Text
- View/download PDF
21. National Drug Laws, Policies, and Programs in India: A Narrative Review.
- Author
-
Parmar, Arpit, Narasimha, Venkata Lakshmi, and Nath, Santanu
- Subjects
DRUG laws ,NARCOTICS ,PUBLIC health ,DRUG utilization ,PSYCHIATRIC drugs - Abstract
Background: Drug use is a major public health issue in India. Significant changes in the approach toward drug use have happened in the last few decades. Despite this, no systematic attempt has been made to document the same in the scientific literature. This narrative review attempts to discuss the major drug laws, policies, and national programs of the Government of India (GoI). Methods: A thorough search was conducted to look for policies, programs, acts, and notifications related to substance use/drug use on various websites of different ministries of the GoI. Acts, programs, and policies addressing substance use were identified. Results: Various drug laws, programs, and acts from the GoI provide a multipronged approach to curbing the procurement of drug use along with its prevention and cure. The Ministry of Social Justice and Empowerment (MoSJE) is the nodal ministry for drug demand reduction. The enactment of the Narcotic Drugs and Psychotropic Substances (NDPS) Act 1985 and Policy 2012 and the implementation of India's Drug De-Addiction Program (DDAP) are important landmarks in this journey. Conclusion: The GoI initiatives for reducing the mental health burden in this country in general and substance use disorders (SUDs), in particular, are immense. The acts/statutes/laws/notifications are all interlinked. Stakeholders in mental health, public health, and policy-making need to upgrade themselves with the relevant statutes to curb the menace of drug use. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. INTERSECTIONALITY MATTERS IN FOOD AND DRUG LAW.
- Author
-
CAMPBELL, COLLEEN
- Subjects
INTERSECTIONALITY ,FOOD laws ,DRUG laws ,SKIN color lighteners ,COSMETICS ,WOMEN of color ,RACISM - Abstract
Feminist scholars critique food and drug law as a site of gender bias and regulatory neglect. The historical exclusion of women from clinical trials by the FDA prioritized male bodies as the object of clinical research and therapies. Likewise, the FDA's prior restriction on access to contraceptive birth control illustrates how patriarchal and paternalistic attitudes within the Agency can harm women's reproductiue health. However, there is little analysis of how race and gender intersect in this domain. This Article uses the regulation of skin-tightening cosmetics products to illustrate why and how intersectionality matters in food and drug law. While the inadequate regulation of cosmetics has a disparate impact on women's health, it is women of color who predominantly use skin-lightening products, similar to some hair care products that are disproportionately marketed to women of color. Additionally, skin-lightening products are often toxic because they contain mercury and other harmful substances. The skin-lightening industry has also historically (and contemporarily) targeted women of color with racist and colorist aduertising messages that idealize light skin as the pinnacle of beauty. The inadequate regulation of cosmetics illustrates why intersectional analysis is essential in food and drug law. An intersectional lens uncouers the various underlying forces that produce a disparate health impact for women of color: systemic racism in health, racially targeted marketing, and hegemonic beauty norms shaped by race and skin color constructs. The increased toxicity of these products also ouerexposes women of color to more serious health risks from cosmetics. While cosmetics reform has ushered in new regulations that improue the Agency's authority to regulate cosmetics, the health risks posed to women of color from toxic personal care products in general deserves urgent attention in food and drug discourses. Intersectional analysis uncouers the contours of this urgency and offers an important response to the de-prioritization of women of color within food and drug law discourses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
23. THE CONGRUITY OF LAWS GOVERNING NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES IN INDIA AND THE WAY FORWARD.
- Author
-
Rab, Aman and Bahuguna, Rajesh
- Subjects
NARCOTICS ,PSYCHOLOGY ,SUBSTANCE abuse ,AGE groups ,COVID-19 pandemic - Abstract
Narcotic drugs and substance abuse have been considered a menace across the world for many decades. The world saw drug addiction or substance abuse as a crime rather than as a medical-legal challenge faced by individuals. However, in the last few years, this perception seems to have transformed from a punitive approach to a reformatory and rehabilitative approach. Most surveys suggest that drug use peaks amongst the age group of 18-25 years. Surveys also indicate a high rate of initiation of drug use amongst adolescents. The importance of the issue is manifest from the fact that 50% of the Indian population is below the age of 25 years and around 65% is below the age of 35 years, and it is expected that the average age of the Indian population would be 29 years by the year 2020. In this paper, the authors have attempted to trace the journey of the NDPS Act and shed light on the issues such as lack of rehabilitation and pendency, which have marred the success of the Act. This paper seeks to analyse the drug laws of India which were enacted to deal with the menace of drug abuse as well as to fulfil its international obligations. Simultaneously, the authors have attempted to bring forth the key factors which seem to have shattered the intent and objectives behind this piece of legislation. The authors have weighed the Act against International Conventions and tried to test its congruity with the rehabilitative approach. Relying on various reports, domestic and global judicial developments and other reliable sources, the authors have attempted to bring forth the challenges which are being faced in dealing with the matters relating to narcotic drugs and substance abuse under the NDPS Act and other ancillary laws and provide some suggestions thereon. [ABSTRACT FROM AUTHOR]
- Published
- 2022
24. Greek myth or fact? The role of Greek houses in alcohol and drug violations on American campuses.
- Author
-
Raghav, Manu and Diette, Timothy M.
- Subjects
SOCIAL groups ,GREEK letter societies ,DRUG laws ,UNIVERSITIES & colleges ,HIGHER education ,LIQUOR laws - Abstract
Greek-letter student social groups, better known as fraternities and sororities, are a ubiquitous feature on many American higher education campuses. These organizations, especially fraternities, have a reputation for encouraging unruly and improper behaviour among both members and non-members. This paper investigates the effect of the degree of prevalence of these Greek organizations at a campus, as measured by the percentage of students who are members of fraternities and sororities, on the instances of liquor and drug law violations on campuses, as measured by the number of arrests for liquor and drug laws violations. Using a unique dataset, which combines data from three sources, we address any potential selection bias by including several controls associated with party culture and through the inclusion of institution-level fixed effects. We find that a larger percentage of students in fraternities (but not sororities) is associated with an increase in the number of arrests for drug law violations. A larger percentage of students in sororities (but not the percentage of students in fraternities) is associated with a larger number of arrests for liquor law violations. This result is highly significant and is robust across various specifications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. The Role of Phosphorylation and Acylation in the Regulation of Drug Resistance in Mycobacterium tuberculosis.
- Author
-
Sun, Manluan, Ge, Sai, and Li, Zhaoyang
- Subjects
MYCOBACTERIUM tuberculosis ,DRUG resistance ,ACYLATION ,DRUG laws ,PHOSPHORYLATION ,ACTIVATED protein C resistance - Abstract
Tuberculosis is a chronic and lethal infectious disease caused by Mycobacterium tuberculosis. In previous decades, most studies in this area focused on the pathogenesis and drug targets for disease treatments. However, the emergence of drug-resistant strains has increased the difficulty of clinical trials over time. Now, more post-translational modified proteins in Mycobacterium tuberculosis have been discovered. Evidence suggests that these proteins have the ability to influence tuberculosis drug resistance. Hence, this paper systematically summarizes updated research on the impacts of protein acylation and phosphorylation on the acquisition of drug resistance in Mycobacterium tuberculosis through acylation and phosphorylation protein regulating processes. This provides us with a better understanding of the mechanism of antituberculosis drugs and may contribute to a reduction the harm that tuberculosis brings to society, as well as aiding in the discovery of new drug targets and therapeutic regimen adjustments in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. The Impact of State Drug Laws on High School Completion and College Enrollment for Latino Young Men.
- Author
-
Britton, Tolani A. and Moreno Luna, Arlyn Y.
- Subjects
COLLEGE enrollment ,DRUG laws ,STATE laws ,MARIJUANA laws ,YOUNG men ,DRUGGED driving - Abstract
Although college enrollment and completion rates have increased over the past 30 years, access to higher education has not been uniform across racial groups. In addition to racial gaps, differences in tertiary education outcomes exist by gender. Gender gaps in college enrollment are larger in the Latinx community than in other racial or ethnic groups. In this paper, we use the October Current Population Survey (CPS) supplements for the years 1984–1992 and state and federal drug laws to measure the impact of the passage of the 1986 Anti-Drug Abuse Act on the likelihood of college enrollment for young Latino men. Following the passage of the federal law, some states changed their drug laws around marijuana and cocaine possession and distribution. We use this variation in state law in order to explore whether states that have more lenient marijuana and cocaine laws also have a higher likelihood of college enrollment. We find that there was a four percentage point decline in both the likelihood of high school completion and that of college enrollment for Latinx men after the passage of the 1986 Anti-Drug Abuse Act. Findings have implications for modifications to state drug laws and addressing the ways in which these laws impact educational attainment for students underrepresented in higher education. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Mediating Medical Marijuana: Exploring How Veterans Discuss Their Stigmatized Substance Use on Reddit.
- Author
-
Rhidenour, Kayla B., Blackburn, Kate, Barrett, Ashley K., and Taylor, Savanna
- Subjects
SUBSTANCE abuse ,SOCIAL support ,SOCIAL media ,SOCIAL stigma ,POST-traumatic stress disorder ,PSYCHOLOGY of veterans ,SELF medication ,DRUG laws ,MEDICAL marijuana ,DRUGS ,SLEEP deprivation ,ONLINE social networks ,HEALTH ,INFORMATION resources ,RESEARCH funding ,THEMATIC analysis ,ANXIETY ,INFORMATION-seeking behavior - Abstract
This paper uses SIDE theory and an information seeking lens to examine the types of information and support messages (N = 126,977 posts) veterans seek on the social networking site Reddit regarding medical marijuana use. A combination of automated text analysis strategies paired with thematic analysis produced eight themes: Doctor Patient Conversations, Drug Test, Legality, Legal Policy, Prescription Drug Use/Other Substance Use, Point of View, Reasons for Use, and V.A. Findings reveal that a large portion of veterans discuss how medical marijuana can be used to self-medicate for a number of issues, including PTSD, anxiety, and sleep deprivation. Results also highlighted missing topics within veterans' conversations about medical marijuana use. For instance, veterans rarely discuss the strategies they use to talk to their doctor about their medical marijuana use. Practical implications and directions for future research are offered. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Accounting as a Normalizing Tool for Transitional Dirtiness: The Case of the US Adult‐Use Cannabis Industry*.
- Author
-
Romi, Andrea M., Carrasco, Heather, Camors, Casey A., and Masselli, John J.
- Subjects
MARIJUANA industry ,DRUG laws ,ACCOUNTING ,GOVERNMENT accounting ,MARIJUANA laws - Abstract
Copyright of Contemporary Accounting Research is the property of Canadian Academic Accounting Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
29. Concerns with current Drug Laws regarding the purchasing antibiotics without a prescription in Pakistan; ways forward to assist the national action plan.
- Author
-
Saleem, Zikria, Sono, Tiyani Milta, and Godman, Brian
- Published
- 2023
- Full Text
- View/download PDF
30. New Findings in Vaccines Described from GlaxoSmithKline plc (An industry perspective on the use of machine learning in drug and vaccine safety).
- Subjects
VACCINE safety ,MACHINE learning ,MEDICATION safety ,SAFETY regulations ,DRUG laws - Abstract
A recent article from GlaxoSmithKline plc discusses the use of machine learning in drug and vaccine safety. The researchers conducted an analysis of 393 papers from a literature search between 2000 and 2021, focusing on industry contributions. The findings revealed that industry is interested in applying machine learning to enhance safety monitoring in pharmacovigilance. The study concludes that although progress has been uneven, there is potential for machine learning to improve patient safety. For more information, readers can refer to the article "An industry perspective on the use of machine learning in drug and vaccine safety" published in Frontiers in Drug Safety and Regulation. [Extracted from the article]
- Published
- 2023
31. Clinical and Molecular Perspectives on Inflammation‐Mediated Regulation of Drug Metabolism and Transport.
- Author
-
Dunvald, Ann‐Cathrine Dalgård, Järvinen, Erkka, Mortensen, Christina, and Stage, Tore B.
- Subjects
METABOLIC regulation ,DRUG metabolism ,DRUG laws ,ENZYME regulation ,INFLAMMATION ,KNOWLEDGE gap theory - Abstract
Inflammation is a possible cause of variability in drug response and toxicity due to altered regulation in drug‐metabolizing enzymes and transporters (DMETs) in humans. Here, we evaluate the clinical and in vitro evidence on inflammation‐mediated modulation of DMETs, and the impact on drug metabolism in humans. Furthermore, we identify and discuss the gaps in our current knowledge. A systematic literature search on PubMed, Embase, and grey literature was performed in the period of February to September 2020. A total of 203 papers was included. In vitro studies in primary human hepatocytes revealed strong evidence that CYP3A4 is strongly downregulated by inflammatory cytokines IL‐6 and IL‐1β. CYP1A2, CYP2C9, CYP2C19, and CYP2D6 were downregulated to a lesser extent. In clinical studies, acute and chronic inflammatory diseases were observed to cause downregulation of CYP enzymes in a similar pattern. However, there is no clear correlation between in vitro studies and clinical studies, mainly because most in vitro studies use supraphysiological cytokine doses. Moreover, clinical studies demonstrate considerable variability in terms of methodology and inconsistencies in evaluation of the inflammatory state. In conclusion, we find inflammation and pro‐inflammatory cytokines to be important factors in regulation of drug‐metabolizing enzymes and transporters. The observed downregulation is clinically relevant, and we emphasize caution when treating patients in an inflammatory state with narrow therapeutic index drugs. Further research is needed to identify the full extent of inflammation‐mediated changes in DMETs and to further support personalized medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Cannabis criminology: inequality, coercion, and illusions of reform.
- Author
-
Wheeldon, Johannes and Heidt, Jon
- Subjects
CANNABIS (Genus) ,RACE ,BEHAVIOR ,CRIMINOLOGY ,DRUG laws ,PARADIGMS (Social sciences) ,GOVERNMENT policy ,THEMATIC analysis ,ETHNIC groups ,CONTROL (Psychology) ,SOCIAL control ,POLICE - Abstract
Cannabis liberalization is a fascinating case study in moral-legal re-negotiation. From broad international examples of decriminalization to specific local legalization models, numerous criminological questions are emerging. This paper describes three significant challenges for cannabis liberalization. These include persistent inequalities associated with policing cannabis, the invisibility of coercive care and control within diversion, and the hazards associated with illusory policy reform. We present Cannabis Criminology as a multidisciplinary effort to understand the prohibition, decriminalization, legalization, and nascent regulation of cannabis in ways that acknowledge but transcend law-based paradigms. Consistent with criminology's multiple and sometimes contradictory dimensions, we outline five thematic areas that can inform the study of cannabis. These include law, society, and social control, police and policing cannabis, race, ethnicity and intrusion, the economics of cannabis use, and cannabis and criminal behavior. Finally, we conclude that privileging the views of people who use cannabis can provoke more inclusive, participatory, and otherwise imaginative efforts. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. 1990年後的曰本藥物濫用防制對策.
- Author
-
陳慈幸
- Subjects
DRUG laws ,DRUG traffic ,DRUG abuse ,NARCOTIC laws ,DRUG control ,PEOPLE with drug addiction - Abstract
Copyright of Angle Health Law Review is the property of Angle Publishing Co., Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
34. Infectious Inflammatory Processes and the Role of Bioactive Agent Released from Imino-Chitosan Derivatives Experimental and Theoretical Aspects.
- Author
-
Himiniuc, Loredana, Socolov, Razvan, Ghizdovat, Vlad, Agop, Maricel, Anton, Emil, Toma, Bogdan, Ochiuz, Lacramioara, Vasincu, Decebal, Popa, Ovidiu, and Onofrei, Viviana
- Subjects
INFLAMMATION ,TISSUE adhesions ,DRUG laws ,ANTIBIOTICS ,MICROBIAL growth ,COVALENT bonds - Abstract
The paper focuses on the development of a multifractal theoretical model for explaining drug release dynamics (drug release laws and drug release mechanisms of cellular and channel-type) through scale transitions in scale space correlated with experimental data. The mathematical model has been developed for a hydrogel system prepared from chitosan and an antimicrobial aldehyde via covalent imine bonds. The reversible nature of the imine linkage points for a progressive release of the antimicrobial aldehyde is controlled by the reaction equilibrium shifting to the reagents, which in turn is triggered by aldehyde consumption in the inhibition of the microbial growth. The development of the mathematical model considers the release dynamic of the aldehyde in the scale space. Because the release behavior is dictated by the intrinsic properties of the polymer–drug complex system, they were explained in scale space, showing that various drug release dynamics laws can be associated with scale transitions. Moreover, the functionality of a Schrödinger-type differential equation in the same scale space reveals drug release mechanisms of channels and cellular types. These mechanisms are conditioned by the intensity of the polymer–drug interactions. It was demonstrated that the proposed mathematical model confirmed a prolonged release of the aldehyde, respecting the trend established by in vitro release experiments. At the same time, the properties of the hydrogel recommend its application in patients with intrauterine adhesions (IUAs) complicated by chronic endometritis as an alternative to the traditional antibiotics or antifungals. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
- Author
-
Lowe, Henry, Toyang, Ngeh, Steele, Blair, Grant, Justin, Ali, Amza, Gordon, Lorenzo, and Ngwa, Wilfred
- Subjects
LSD (Drug) ,PSILOCYBIN ,ANXIETY disorders ,AFFECTIVE disorders ,HALLUCINOGENIC drugs ,DRUG laws - Abstract
The word "psychedelic" (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic drugs such as N,N-DMT/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), MDMA (3,4-methylenedioxymethamphetamine) and psilocybin have had significant value as an entheogen in spiritual, religious (shamanic) and sociocultural rituals in Central and South American cultures for thousands of years. In the 1960s, the globalization of these drugs and their subsequent spread outside of their indigenous, old-world cultures, led to the subsequent implementation of strict drug control laws in many Western countries. Even today, psychedelics are still classified as Schedule I drugs, resulting in a still lingering negative stigmatization/perception, vilification, and ultimate criminalization of psychedelics. This controversy still lingers and still limits scientific research and full medical acceptance. For many years up until recently, the spiritual, religious and medicinal value of these drugs could not be explored in a scientific context. More recently, a second wave of psychedelic research is now focusing on psychedelics as neuropharmaceuticals to treat alcohol and tobacco addiction, general mood and anxiety disorders and cancer-related depression. There is now a vast array of promising evidence-based data to confirm the years of anecdotal evidence of the medicinal values of psychedelics. Natural therapeutic alternatives such as psychedelic drugs may provide a safe and efficacious alternate to conventional drugs used to treat mood and anxiety disorders. In a Western context in particular, psychedelic drugs as therapeutic agents for mood and anxiety disorders are becoming increasingly of interest amidst increasing rates of such disorders globally, changing social constructions, the implementation of government regulations and increasing investment opportunities, that ultimately allow for the scientific study to generate evidenced-based data. Alternative psychotherapeutic interventions are gaining interest also, because of their low physiological toxicity, relatively low abuse potential, safe psychological effects, and no associated persisting adverse physiological or psychological effects during and after use. On the other hand, conventional psychotic drugs and anti-depressants are becoming less favorable because of their adverse side effects. Psychedelic neuropharmaceutical interventions may with medical oversight be the solution to conventional psychiatric disorders such as depression and anxiety, and an alternative to conventional psychiatric treatment options. This paper will review the therapeutic potential of psychedelic drugs as alternative therapeutic options for mood and anxiety disorders in a controlled, clinical setting, where the chances of adverse psychological episodes occurring are mitigated. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. RESPONSE TO LISTENING TO MIFEPRISTONE.
- Author
-
DONLEY, GREER and ZETTLER, PATRICIA J.
- Subjects
MIFEPRISTONE ,ABORTION ,DRUG laws ,ACTIONS & defenses (Law) - Published
- 2023
37. State Drug Testing Laws for Opioid Therapy: Implications for Employment-Based Health Plans.
- Author
-
Volkov, Eden, Gamino, Aaron M., and Fronstin, Paul
- Subjects
PAIN management ,EMPLOYEE drug testing ,DRUG laws ,DRUG use testing ,NARCOTIC laws ,HEALTH insurance laws ,OPIOIDS ,PATENT offices ,LAW offices - Abstract
The article focuses on the impact of state drug testing laws on opioid therapy patients and their implications for employment-based health plans. It highlights that state drug testing laws increase testing rates among chronic pain patients prescribed opioids but have no impact on opioid prescribing rates, suggesting that these laws are an important diagnostic tool for doctors in treating employees most in need of opioid therapy.
- Published
- 2023
38. Weak regulations threaten the safety of consumers from harmful weight-loss supplements globally: results from a pilot global policy scan.
- Author
-
Okoya, Funmbi T, Santoso, Monique, Raffoul, Amanda, Atallah, Maya Azar, and Bryn Austin, S
- Subjects
CONSUMERS ,CONSUMER protection ,DRUG laws ,SAFETY regulations - Abstract
Objective: To pilot a global policy scan assessing how governments worldwide regulate weight-loss supplements (WLS). Design: Experts on WLS policies from thirty countries that varied by World Bank income classification, with five from each of the six WHO regions, completed an online survey on WLS regulation in their country. The survey covered six domains: legal frameworks; pre-market requirements; claims, labelling, and advertisements; product availability; adverse events reporting; and monitoring and enforcement. Percentages were calculated for presence or absence of a type of regulation. Setting: Experts were recruited through websites of regulatory bodies and professional LinkedIn networks and scientific article searches on Google Scholar. Participants: Thirty experts, one from each country (i.e. researchers, regulators, other experts in food and drug regulation). Results: WLS regulations varied widely across countries, and a number of gaps were identified. One country (Nigeria) has a minimum legal age to purchase WLS. Thirteen countries reported independently evaluating the safety of a new WLS product sample. Two countries have limitations on where WLS can be sold. In eleven countries, reports on adverse events related to WLS are publicly available. In eighteen countries, safety of new WLS is to be established through scientific criteria. Penalties for WLS non-compliance with pre-market regulations exist in twelve countries and labelling requirements in sixteen countries. Conclusions: Results of this pilot study document wide variability in national WLS regulations globally, exposing many gaps in important components of consumer protection regulatory frameworks for WLS, which likely put consumer health at risk. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. Red flaging unscientific prescriptions in dermatophytosis: An overview.
- Author
-
Das, Anupam, Praveen, Pranjal, Khurana, Ananta, and Sardana, Kabir
- Subjects
RINGWORM ,DRUG approval ,PROFESSIONS ,NONPRESCRIPTION drugs ,DRUG laws ,DERMATOLOGIC agents ,DRUGS ,DRUG prescribing ,MEDICAL ethics ,PHYSICIAN practice patterns - Abstract
Dermatophytosis has acquired an epidemic-like proportion, fuelling a wide gamut of irrational, unethical and unscientific prescriptions. The menace can be attributed to poorly regulated legislative laws controlling the approval of molecules, unscientific marketing gimmicks by the pharmaceutical industry, over-the-counter availability of drugs and lack of awareness and knowledge among the prescribing physicians. In this review, we have attempted to enlist the irrational and unethical prescription patterns for dermatophytosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Evaluating and understanding the outcomes of the South African National Drug Master Plan 2013–2017: A systems‐based integrative propositional analysis application.
- Subjects
SUBSTANCE abuse prevention ,MEDICAL policy laws ,DRUG laws ,HEALTH policy ,RISK-taking behavior ,POLICY analysis ,EVALUATION of human services programs ,GOVERNMENT programs ,HARM reduction ,CONCEPTUAL structures ,DRUGS ,HEALTH promotion - Abstract
A balanced approach using an integrated combination of strategies, namely, demand reduction, supply reduction and harm reduction, was suggested to be implemented in a balanced way to the policy vision of a South Africa 'free of substance abuse'. Responding on the call for a comprehensive review of the National Drug Master Plan 2013–2017 to ensure consistency in policy approach, this article explores the integrative propositional analysis (IPA)‐based analysis to evaluate 'how systemic' and integrated were the policy strategies applied. The analysis draws insights from the internal consistency of the policy and provides complementary evidence on the systemic breakdown of the policy, which correlates with previous studies. The findings are indicative of the usefulness of the IPA‐based tools to more pragmatically develop policy that better reflects the systemic/integrated relationship of the three strategies based on their conceptual systemic integrity. This research has implications for interdisciplinary scholars and practitioners, of policy and theory. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Anthroposophic Medicinal Products: A Literature Review of Features, Similarities and Differences to Conventional Medicinal Products, Scientific and Regulatory Assessment.
- Author
-
Baars, Erik W., Kienle, Gunver S., Heusser, Peter, Pedersen, Peter A., Wietmarschen, Herman A. van, Kiene, Helmut, von Schoen-Angerer, Tido, and Hamre, Harald J.
- Subjects
ANTHROPOSOPHY ,INTEGRATIVE medicine ,SCIENTIFIC community ,PHYSICIAN practice patterns ,DRUG laws - Abstract
Background: Regulatory assessment of anthroposophic medicinal products (AMPs) can be challenging due to their specific features. Objective: The aim of this paper is therefore to provide adequate scientific information on AMPs for regulatory purposes. Methods: A literature review was executed with database searches in PubMed, Cinahl, Merkurstab, Anthromedics, and https://iaap-pharma.org/. Search terms were: anthroposophic medicinal products, anthroposophic medicines, anthroposophic pharmacy. There was no language restriction; searches were executed from onset until June 11, 2020. In addition, experts were invited to suggest relevant literature. Results: Eighty-seven of 660 identified publications were included. The system of anthroposophic medicine (AM) with its conceptual background and various aspects of AMPs was described: definition, pharmaceutical properties, an example of AMP development, use in clinical practice, similarities with and differences to conventional medicinal products, societal aspects, scientific and regulatory assessment. Conclusion: AMPs are part of the integrative whole medical system of AM. AMPs are manufactured according to Good Manufacturing Practice and national drug regulations and have an excellent safety status; the limited available evidence suggests clinical benefits. Current drug regulation of AMPs in the EU and most European countries does not take the special properties of AMPs into account. Future research should focus on appropriate methodologies for the evaluation of effects of AMPs as part of the AM whole medical system, the scientific quality of its non-atomistic holistic ontological position, and the integration of AM and conventional medicine in clinical practice. Future policies should focus on appropriate ways of addressing regulatory challenges to AMPs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
42. Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law.
- Author
-
Danieli, Diletta
- Subjects
DRUG laws ,PHARMACEUTICAL industry ,ANTITRUST law ,PUBLIC health ,EUROPEAN law - Abstract
The paper addresses the issue of excessive price abuse under Article 102(a) of the Treaty on the Functioning of the European Union (TFEU), by drawing inspiration from a recent stream of cases (developed first at the national and then at the EU level) involving pharmaceutical companies marketing off-patent drugs. In particular, the two 'most advanced' cases are analysed: Aspen in Italy and Pfizer/Flynn in the United Kingdom. This new-found attention towards exploitative practices in the form of excessive and unfair pricing by dominant undertakings that have traditionally been subject to a cautious antitrust scrutiny seems worth exploring for a number of reasons, as illustrated in the paper. Ultimately, it is argued that this further 'interference' of competition law into the realms of regulation may be actually justified, albeit subject to precise conditions for enforcement, and may pursue policy objectives in the wider context of EU health law. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
43. Dynamic regulation of drug biodistribution by turning tumors into decoys for biomimetic nanoplatform to enhance the chemotherapeutic efficacy of breast cancer with bone metastasis.
- Author
-
Cuixia Zheng, Dandan Zhang, Yueyue Kong, Mengya Niu, Hongjuan Zhao, Qingling Song, Qianhua Feng, Xingru Li, and Lei Wang
- Subjects
METASTATIC breast cancer ,DRUG laws ,CANCER pain ,CANCER chemotherapy ,STERNUM - Abstract
Breast cancer with bone metastasis accounts for serious cancer-associated pain which significantly reduces the quality of life of affected patients and promotes cancer progression. However, effective treatment using nanomedicine remains a formidable challenge owing to poor drug delivery efficiency to multiple cancer lesions and inappropriate management of cancer-associated pain. In this study, using engineered macrophage membrane (EMM) and drugs loaded nanoparticle, we constructed a biomimetic nanoplatform (EMM@DJHAD) for the concurrent therapy of bone metastatic breast cancer and associated pain. Tumor tropism inherited from EMM provided the targeting ability for both primary and metastatic lesions. Subsequently, the synergistic combination of decitabine and JTC801 boosted the lytic and inflammatory responses accompanied by a tumoricidal effect, which transformed the tumor into an ideal decoy for EMM, resulting in prolonged troop migration toward tumors. EMM@DJHAD exerted significant effects on tumor suppression and a pronounced analgesic effect by inhibiting μ-opioid receptors in bonemetastasismousemodels.Moreover, the nanoplatformsignificantly reduced the severe toxicity induced by chemotherapy agents. Overall, this biomimetic nanoplatform with good biocompatibility may be used for the effective treatment of breast cancer with bone metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. On pharmacological neuroenhancement as part of the new neurorights’ pioneering legislation in Chile: a perspective.
- Author
-
Isabel Cornejo-Plaza, María and Saracini, Chiara
- Subjects
CONSTITUTIONAL reform ,DRUG laws ,ETHICAL problems ,CIVIL rights ,HUMAN rights - Abstract
The so-called neurorights are emerging human rights, or rather reconfigurations of already existing human rights, seeking to address the impact of the possible misuse of neurotechnologies, which have the potential to become more invasive and harmful in the future if not regulated. The aim of specifying neurorights is to protect the dignity and autonomy of the individual in the face of neurotechnological advances. Recently, Chile proposed a Constitutional reform inspired by the neurorights, opening a debate. One of the proposed neurorights is fair and equitable access to cognitive enhancement, which will be the specific object of this perspective article. Starting from the legal proposal, we analyse and discuss some perspectives on cognitive enhancement, or “neuroenhancement”, which could be considered as part of enhancement neurotechnologies, pointing out that pharmacological enhancers, or “smart drugs”, might be considered as part of these enhancers. We present a classification of the dierent types of cognitive enhancements as it has been proposed in the literature, into which pharmacological cognitive enhancement can be included, concluding that there is currently no agreement amongst scholars and lawyers about the ethical consideration of pharmacological cognitive enhancement. We therefore argue that it is necessary for the legislator to explicitly address the issue in the proposed regulations, in order to take a clear position on the topic, as it has been done in the United Kingdom, where the pharmacological neuroenhancers have been explicitly excluded from the regulation. If pharmacological neuroenhancers are going to be considered neurotechnologies, then new law proposals should seek harmonization with the already existing legislation regulating pharmacological health and consumer rights (both globally, taking into account international drug laws, and locally, according to each country’s internal regulations) and of course, with the whole system of fundamental rights. Finally, we briefly discuss the ethical problem of equitable access to this new type of neurotechnologies (as part of the neurorights) and leave the debate open for new insights from the scientific community on the possible consequences of including (or not) pharmacological neuroenhancers as neurotechnologies for cognitive enhancement in the framework of the ethical and legal debate. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD).
- Author
-
Wu, Liusheng, Liu, Qi, Ruan, Xin, Luan, Xinyu, Zhong, Yanfeng, Liu, Jixian, Yan, Jun, and Li, Xiaoqiang
- Subjects
DRUG laws ,ADENOCARCINOMA ,CLINICAL drug trials ,NILOTINIB ,DISEASE risk factors ,ORGANELLE formation ,SORAFENIB ,PANCREATIC intraepithelial neoplasia - Abstract
Objective: The RNA-binding protein RBM10 can regulate apoptosis during the proliferation and migration of pancreatic cancer, endometrial cancer, and osteosarcoma cells; however, the molecular mechanism underlying lung adenocarcinoma is rarely reported. Recent studies have detected multiple truncated and missense mutations in RBM10 in lung adenocarcinoma, but the role of RBM10 in lung adenocarcinoma is unclear. This study mainly explored the immune regulation mechanism of RBM10 in the development of lung adenocarcinoma and its influence on sensitivity to targeted therapy drugs. Methods: The transcriptome data of CGAP were used to analyze the RNA-seq data of lung adenocarcinoma patients from different subgroups by using the CIBERSORT algorithm to infer the relative proportion of various immune infiltrating cells, and Spearman correlation analysis was performed to determine the gene expression and immune cell content. In addition, this study utilized drug trial data from the GDSC database. The IC50 estimates for each specific targeted therapy were obtained by using a regression method, and the regression and prediction accuracy were tested via ten cross-validations with the GDSC training set. An immunohistochemical test was performed on the samples of 20 patients with lung adenocarcinoma in the subcomponent analysis of immune cells, and the protein expression of RBM10 in lung adenocarcinoma tissues was verified by cellular immunofluorescence assays. Nucleic acids were extracted at low temperatures, and qRT-PCR was used to verify the expression levels of the mRNA of RBM10 in lung adenocarcinoma tissues and normal tissues (p < 0.05). Results: After screening and inclusion using a machine language, the results showed that RBM10 was significantly highly expressed in the lung adenocarcinoma tissues. The related signaling pathways were mainly concentrated in ncRNA processing, rRNA metabolic processes, ribosome biogenesis, and the regulation of translation. The qRT-PCR for 20 lung adenocarcinoma tissues showed that the expression of RBM10 in these tissues was significantly different from that in normal tissues (p = 0.0255). Immunohistochemistry analysis and cell immunofluorescence staining also confirmed that RBM10 was involved in the immune regulation of lung adenocarcinoma tissues, and the number of immune cell aggregations was significantly higher than that of the control group. RBM10 regulates B cell memory-CIBERSORT (p = 0.042) and B cell memory-CIBERSOTRT-abs (p = 0.027), cancer-associated fibroblast-EPIC (p = 0.001), cancer-associated fibroblast- MCPCounter (p = 0.0037), etc. The risk score was significantly associated with the sensitivity of patients to lapatinib (p = 0.049), nilotinib (p = 0.015), pazopanib (p = 0.001), and sorafenib (p = 0.048). Conclusions: RBM10 can inhibit the proliferation and invasion of lung adenocarcinoma cells through negative regulation and promote the apoptosis of lung adenocarcinoma cells through immunomodulatory mechanisms. The expression level of RBM10 affects the efficacy of targeted drug therapy and the survival prognosis of lung adenocarcinoma patients, which has a certain guiding significance for the clinical treatment of these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Use of Physiologically Based Pharmacokinetic Modeling for Hepatically Cleared Drugs in Pregnancy: Regulatory Perspective.
- Author
-
Coppola, Paola, Kerwash, Essam, and Cole, Susan
- Subjects
LIVER physiology ,PHARMACOKINETICS ,CYTOCHROME P-450 ,METABOLIC clearance rate ,GOVERNMENT regulation ,LIVER ,DRUG laws ,GOVERNMENT agencies ,RESEARCH funding ,PREGNANCY - Abstract
Physiologically based pharmacokinetic modeling could be used to predict changes in exposure during pregnancy and possibly inform medicine use in pregnancy in situations in which there is currently limited or no available clinical PK data. The Medicines and Healthcare Product Regulatory Agency has been evaluating the available models for a number of medicines cleared by hepatic clearance mechanisms. Models were evaluated for metoprolol, tacrolimus, clindamycin, ondansetron, phenytoin, caffeine, fluoxetine, clozapine, carbamazepine, metronidazole, and paracetamol. The hepatic metabolism through cytochrome P450 (CYP) contributes significantly to the elimination of these drugs, and available knowledge of CYP changes during pregnancy has been implemented in the existing pregnancy physiology models. In general, models were able to capture trends in exposure changes in pregnancy to some extent, but the magnitude of pharmacokinetic change for these hepatically cleared drugs was not captured in each case, nor were models always able to capture overall exposure in the populations. A thorough evaluation was hampered by the lack of clinical data for drugs cleared by a specific clearance pathway. The limited clinical data, as well as complex elimination pathways involving CYPs, uridine 5′‐diphospho‐glucuronosyltransferase and active transporter for many drugs, currently limit the confidence in the prospective use of the models. Pregnancy‐related changes in uridine 5′‐diphospho‐glucuronosyltransferase and transport functions are emerging, and incorporation of such changes in current physiologically based pharmacokinetic modeling software is in progress. Filling this gap is expected to further enhance predictive performance of models and increase the confidence in predicting PK changes in pregnant women for hepatically cleared drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. Beyond the Auditable: Pathology, Professional Vision, and the Limits of Oversight for Regulating Psychotropic Drugs in Foster Care.
- Author
-
Gibson, Katherine
- Subjects
FOSTER home care ,PSYCHIATRIC drugs ,FOSTER children ,CHILD welfare ,PATHOLOGY ,DRUG laws - Abstract
This article draws from an 18-month ethnographic study of professional practices with psychotropic drugs in Illinois to demonstrate how psychotropic drugs are framed in policy and regulated in practice. I first show that disordered youth—rather than dysfunctional institutions—have been centered as the object of policy intervention. I then illustrate that whereas centering the disordered child as an object of intervention in public discourse requires one set of discursive maneuvers, another set of practices—namely, audits—is required to center the child as an object of knowledge around which professionals are organized. As auditors elicit treatment rationales in which drugs treat neurochemical disorder, prescribers and other professionals learn to represent youth in ways that pathologize them. Although audits can play an important role in the regulation of psychotropic drugs in foster care, child welfare systems must address the limits of audits, as well as their unintended effects. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. A nonmetal substrate of surface‐enhanced Raman spectroscopy for trace fentanyl detection.
- Author
-
Lian, Zheng, Lu, Chunqing, Sun, Qian, Cheng, Jiaolong, Miao, Cuiying, and Chen, Zhenqian
- Subjects
FENTANYL ,DESIGNER drugs ,SERS spectroscopy ,NONMETALS ,DRUG laws ,CHEMICAL stability ,FORENSIC sciences - Abstract
Rapid detection and identification of opioids are of great significance and an urgent need in drug regulation and forensic science. Fentanyl is an extremely potent synthetic drug of abuse that unfortunately cannot be accurately detected. Therefore, techniques combining fast, highly sensitive and portable for fentanyl detection need to be developed. Surface‐enhanced Raman spectroscopy (SERS) has emerged as a promising detection technique owing to its high sensitivity and selectivity. Here, we reported a nonmetal SERS substrate used for trace fentanyl detection. The lowest detectable concentration was 10−7 M, and the MoO2 substrate exhibited excellent thermal and chemical stability, which could even ensure high‐temperature heating, laser irradiation, and corrosion of strong acid or alkali. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. Physicians’ legal duty to disclose more cost-effective treatment options: an examination of Australian civil law applied to personal importation.
- Author
-
Ghinea, Narcyz
- Subjects
DRUG laws ,DISCLOSURE ,HEALTH services accessibility ,HUMAN research subjects ,MEDICAL care costs ,COST benefit analysis ,RESPONSIBILITY ,INFORMED consent (Medical law) ,DRUGS ,AUSTRALIANS ,DRUG prescribing ,NEGLIGENCE ,MEDICAL ethics ,PHYSICIANS ,PHYSICIAN practice patterns - Abstract
Objective. A significant proportion of Australians defer or do not fill prescriptions they require due to cost. This article explores whether, and under what circumstances, physicians have a duty to assist these patients by disclosing how they can access more affordable medicines via personal importation. Methods. This study involved a critical examination of Australian statutory and case law pertaining to physicians’ duty to disclose material information to identify key principles applicable to the context of cost-motivated personal importation. Results. There are several legal principles that suggest that physicians have a duty to advise patients of options for accessing more affordable medicines, including via personal importation. These include a duty to warn of inherent and non-inherent risks, a duty to disclose treatments that offer clear advantages, and a duty to facilitate access to the means for achieving patients’ health goals. However, it is unclear whether, and on what grounds, responsibility for harm arising from a patient's inability to afford prescribed medicines should be attributed to the prescribing physician. Arguments supporting attribution of such a responsibility are proposed to motivate further legal, policy and ethical debate. Conclusions. Physicians have a duty to take reasonable steps to mitigate foreseeable harm to their patients, however the law is silent on whether this duty extends to taking steps to help patients access medicines that they can afford. This investigation provides a framework to guide the development of sound policy and law on informed financial consent and economically motivated prescribing. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. Analysis of the UK Government's 10-Year Drugs Strategy—a resource for practitioners and policymakers.
- Author
-
Holland, Adam, Stevens, Alex, Harris, Magdalena, Lewer, Dan, Sumnall, Harry, Stewart, Daniel, Gilvarry, Eilish, Wiseman, Alice, Howkins, Joshua, McManus, Jim, Shorter, Gillian W, Nicholls, James, Scott, Jenny, Thomas, Kyla, Reid, Leila, Day, Edward, Horsley, Jason, Measham, Fiona, Rae, Maggie, and Fenton, Kevin
- Subjects
SUBSTANCE abuse prevention ,SUBSTANCE abuse risk factors ,HEALTH policy ,ADVERSE childhood experiences ,SUBSTANCE abuse ,HUMAN rights ,TREATMENT programs ,HEALTH services accessibility ,GOVERNMENT regulation ,SUBSTANCE abuse treatment ,PUBLIC health ,DRUG laws ,HARM reduction ,SOCIOECONOMIC factors ,RISK assessment ,GOVERNMENT aid - Abstract
In 2021, during a drug-related death crisis in the UK, the Government published its ten-year drugs strategy. This article, written in collaboration with the Faculty of Public Health and the Association of Directors of Public Health, assesses whether this Strategy is evidence-based and consistent with international calls to promote public health approaches to drugs, which put 'people, health and human rights at the centre'. Elements of the Strategy are welcome, including the promise of significant funding for drug treatment services, the effects of which will depend on how it is utilized by services and local commissioners and whether it is sustained. However, unevidenced and harmful measures to deter drug use by means of punishment continue to be promoted, which will have deleterious impacts on people who use drugs. An effective public health approach to drugs should tackle population-level risk factors, which may predispose to harmful patterns of drug use, including adverse childhood experiences and socioeconomic deprivation, and institute evidence-based measures to mitigate drug-related harm. This would likely be more effective, and just, than the continuation of policies rooted in enforcement. A more dramatic re-orientation of UK drug policy than that offered by the Strategy is overdue. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.